FTC Approves Final Order in Hikma Pharmaceuticals plc’s $375 Million Acquisition of Custopharm, Inc.
WASHINGTON D.C. — Following a public comment period, the Federal Trade Commission recently approved a final order settling charges that Hikma Pharmaceuticals plc’s $375 million acquisition of Custopharm, Inc. likely would have …
FTC Approves Final Order in Hikma Pharmaceuticals plc’s $375 Million Acquisition of Custopharm, Inc. Read More